プロスタグランジン

ビマトプロスト CAS 155206-00-1

お見積もり

ビマトプロスト CAS 155206-00-1

ビマトプロスト
155206-00-1

プロスタグランジン＆中間体

パッケージは1kg/袋から25kg/ドラムまでご要望に応じます。.

ご希望により、分子を変更可能（グラムからキロスケール）。.

製品名

ビマトプロスト

CAS番号.

155206-00-1

純度

NLT 99.0%

パッケージ

パッケージは1kg/袋から25kg/ドラムまでご要望に応じます。.

分子式

C25H37NO4

分子量

415.6

スマイル

ccnc(=o)ccc/c=cc[c@h]1[c@h](c[c@h]([c@h]1/c=c/[c@h](ccc2=cc=cc=c2)o)o)o

IUPAC名

(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide

同義語

Bimatoprost; 155206-00-1; Lumigan; Latisse; AGN 192024; Prostamide; bimatoprostum; AGN-192024; DURYSTA; QXS94885MZ; CHEBI:51230; (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide; DTXSID30895042; GANFORT COMPONENT BIMATOPROST; AGN192024; 5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-; (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide; (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-N-ethylhept-5-enamide; (5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)-N-ethylhept-5-enamide; (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((E,3S)-3-hydroxy-5-phenylpent-1-enyl)cyclopentyl)-N-ethylhept-5-enamide; (Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-5-heptenamide; 192024, AGN; RefChem:54542; S01EE03; DTXCID401324598; 5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-,(5Z)-; Lumigan (TN); MFCD03411999; (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)-N-ethylhept-5-enamide; 5-Heptenamide, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-, (5Z)-; (E)-7-[3,5-dihydroxy-2-[(E)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide; UNII-QXS94885MZ; (5z)-7-{(1r,2r,3r,5s)-3,5-Dihydroxy-2-[(1e,3s)-3-Hydroxy-5-Phenylpent-1-Enyl]cyclopentyl}-N-Ethylhept-5-Enamide; Bimatoprost [USAN:INN:BAN:JAN]; Bimatoprost in bulk; Latisse (TN); LS-181817; BIMATOPROST [MI]; BIMATOPROST [INN]; BIMATOPROST [JAN]; (5Z)-BIMATOPROST; BIMATOPROST [USAN]; BIMATOPROST [VANDF]; BIMATOPROST [MART.]; SCHEMBL24425; BIMATOPROST [WHO-DD]; MLS006010039; US9271961, Bimatoprost; Bimatoprost (JAN/USAN/INN); BIMATOPROST [EMA EPAR]; GTPL1958; orb1305342; CHEMBL1200963; BIMATOPROST [ORANGE BOOK]; BDBM220120; GLXC-05106; EX-A1769; HY-B0191; MSK159263; AKOS015995566; DB00905; FB18599; FD10460; NCGC00181745-01; NCGC00181745-03; (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenyl-pent-1-enyl]cyclopentyl]-N-ethyl-hept-5-enamide; 5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (5Z)-; 5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-1(alpha(Z),2beta(1E,3S*)3alpha,5alpha))-; AS-35082; SMR000058996; B6165; NS00007742; D02724; SBI-0654129.0001; 206B001; EN300-21680860; SR-01000942224; Q2393348; SR-01000942224-1; 17-PHENYL TRINOR PROSTAGLANDIN F2ALPHA ETHYL AMIDE; 17-Phenyl-tri-norprostaglandin F2alpha-ethyl amide, >=95%, solid; (5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-5-heptenamide;AGN-192024;Lumiga n; 15M; 5-Heptenamide, 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl]-N-ethyl-, [1R-[1alpha(Z),2beta(1E,3S*),3alpha,5alpha]]-; Bimatoprost/Lumigan; AC1NSJUW; D0Q2XF; C25H37NO4; AQOKCDNYWBIDND-FTOWTWDKSA-N; Bimataprost [USAN:INN:BAN]; Bimatoprost [USAN:INN:BAN]; Bimatoprost (topical, alopecia); ZINC4474405; ABP000616; C25-H37-N-O4; ACN-037134; AM84507; AN-5283; CID5311027; CS-2085; CS-O-11612; RP17728; CID:5311027; M052; SID:283537485; AB0015029; FT-0650396; A809623; C420823; 17-Phenyl-tri-norprostaglandin F2alpha-ethyl amide; I06-1275; I06-1277; D000069580; B0084-340237; (5E)-5-[4-(difluoromethoxy)benzylidene]-2-mercapto-1,3-thiazol-4(5H)-one; (5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-5-heptenamide; 5-Heptenamide, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-, (5Z)- (9CI); AGN 192024; Bimatoprost; Latisse; Lumigan; Prostamide; 5-Heptenamide, 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl]-N-ethyl-, [1R-[1alpha(Z),2beta(1E,3S*),3alpha,5alpha]]-; 17-Phenyltrinor-PGF2alpha ethylamide; (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprosta-5,13-dienoic acid ethylamide; (E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide; 5-Heptenamide,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ehtyl-,(5Z)